Deepak Sampath

15.1k total citations · 1 hit paper
110 papers, 5.0k citations indexed

About

Deepak Sampath is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Deepak Sampath has authored 110 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Molecular Biology, 33 papers in Oncology and 24 papers in Genetics. Recurrent topics in Deepak Sampath's work include PI3K/AKT/mTOR signaling in cancer (27 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Acute Myeloid Leukemia Research (11 papers). Deepak Sampath is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (27 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Acute Myeloid Leukemia Research (11 papers). Deepak Sampath collaborates with scholars based in United States, France and Canada. Deepak Sampath's co-authors include Lori S. Friedman, Carter T. Fields, Gail D. Lewis Phillips, Mark X. Sliwkowski, Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Dwight C. Look, Michael J. Holtzman and Mario Castro and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Deepak Sampath

106 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

2009 651 citations Teemu T. Junttila, Robert W. Akita et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deepak Sampath United States	37	2.9k	1.9k	845	796	553	110	5.0k
Dale L. Ludwig United States	36	4.4k 1.5×	1.6k 0.9×	993 1.2×	850 1.1×	430 0.8×	91	5.9k
Young E. Whang United States	39	3.2k 1.1×	1.7k 0.9×	874 1.0×	1.5k 1.9×	312 0.6×	101	5.6k
Donald L. Durden United States	38	3.3k 1.1×	1.1k 0.6×	1.0k 1.2×	375 0.5×	776 1.4×	108	5.3k
Peter Blume‐Jensen United States	18	3.3k 1.1×	1.3k 0.7×	454 0.5×	561 0.7×	384 0.7×	25	5.0k
Guenther Gastl Austria	38	1.6k 0.5×	2.2k 1.2×	669 0.8×	460 0.6×	554 1.0×	110	4.9k
Anne W. Hamburger United States	29	2.7k 0.9×	2.2k 1.2×	764 0.9×	555 0.7×	216 0.4×	110	4.9k
Percy Ivy United States	36	1.9k 0.6×	1.5k 0.8×	869 1.0×	883 1.1×	731 1.3×	120	4.5k
Paul Frankel United States	34	1.8k 0.6×	1.9k 1.0×	658 0.8×	967 1.2×	250 0.5×	214	4.1k
Suzanne F. Jones United States	42	3.6k 1.2×	4.1k 2.2×	1.1k 1.3×	1.8k 2.2×	699 1.3×	231	7.8k
Lynn G. Feun United States	39	2.2k 0.8×	1.8k 1.0×	1.1k 1.2×	817 1.0×	647 1.2×	207	5.7k

Countries citing papers authored by Deepak Sampath

Since Specialization

Citations

This map shows the geographic impact of Deepak Sampath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepak Sampath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepak Sampath more than expected).

Fields of papers citing papers by Deepak Sampath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepak Sampath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepak Sampath. The network helps show where Deepak Sampath may publish in the future.

Co-authorship network of co-authors of Deepak Sampath

This figure shows the co-authorship network connecting the top 25 collaborators of Deepak Sampath. A scholar is included among the top collaborators of Deepak Sampath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepak Sampath. Deepak Sampath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hagenbeek, Thijs J., Ho-June Lee, Jason Li, et al.. (2020). Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways. Cancer Discovery. 11(3). 778–793. 37 indexed citations

Zervantonakis, Ioannis K., Laura M. Selfors, Sangeetha Palakurthi, et al.. (2019). Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Molecular Cancer Therapeutics. 18(3). 642–655. 36 indexed citations

Zoeller, Jason J., Krishan Taneja, Benjamin Y. Tan, et al.. (2019). Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Molecular Cancer Therapeutics. 18(6). 1115–1126. 25 indexed citations

Rahmani, Mohamed, Xin‐Yan Pei, Rebecca E. Parker, et al.. (2018). Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Research. 78(11). 3075–3086. 112 indexed citations

Juric, Dejan, Ian E. Krop, Ramesh K. Ramanathan, et al.. (2017). Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery. 7(7). 704–715. 120 indexed citations

Mali, Raghuveer Singh, Elisabeth A. Lasater, Kelly Doyle, et al.. (2017). FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models. Blood. 130. 1348–1348. 17 indexed citations

Punnoose, Elizabeth A., Joel Johansson, Franklin Peale, et al.. (2016). Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics. 15(5). 1132–1144. 223 indexed citations

Misner, Dinah, M. Ariel Kauss, Jatinder Singh, et al.. (2016). Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines. Cardiovascular Toxicology. 17(3). 307–318. 18 indexed citations

Tan, Nguyen, Michelle Nannini, Rebecca Hong, et al.. (2013). Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models. Molecular Cancer Therapeutics. 12(6). 853–864. 61 indexed citations

10.

Wallin, Jeffrey J., Jane Guan, Wei Wei Prior, et al.. (2012). GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo. Clinical Cancer Research. 18(14). 3901–3911. 73 indexed citations

11.

Spoerke, Jill M., Carol O’Brien, Ling Huw, et al.. (2012). Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. Clinical Cancer Research. 18(24). 6771–6783. 149 indexed citations

12.

Chen, Jun, Sha Jin, Xiaoli Huang, et al.. (2011). The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo. Molecular Cancer Therapeutics. 10(12). 2340–2349. 119 indexed citations

13.

Tan, Nguyen, Jiping Zha, Yue Peng, et al.. (2011). Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models. Clinical Cancer Research. 17(6). 1394–1404. 83 indexed citations

14.

Edgar, Kyle A., Jeffrey J. Wallin, Megan Berry, et al.. (2010). Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors. Cancer Research. 70(3). 1164–1172. 94 indexed citations

15.

Fields, Carter T., Guangmin Li, Wei Wei Prior, et al.. (2009). Abstract #3239: Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase. Cancer Research. 69. 3239–3239. 3 indexed citations

16.

Junttila, Teemu T., Robert W. Akita, Kathryn L. Parsons, et al.. (2009). Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell. 15(5). 429–440. 651 indexed citations breakdown →

17.

Schwalm, Mark, et al.. (2005). Cryogenic telescope, scanner, and imaging optics for the wide-field infrared survey explorer (WISE). Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 5904. 59040K–59040K. 8 indexed citations

18.

Sampath, Deepak. (2001). Cyr61, a Member of the CCN Family, Is Required for MCF-7 Cell Proliferation: Regulation by 17 -Estradiol and Overexpression in Human Breast Cancer. Endocrinology. 142(6). 2540–2548. 19 indexed citations

19.

Sampath, Deepak, Richard C. Winneker, & Zhiming Zhang. (2001). Cyr61, a Member of the CCN Family, Is Required for MCF-7 Cell Proliferation: Regulation by 17β-Estradiol and Overexpression in Human Breast Cancer. Endocrinology. 142(6). 2540–2548. 90 indexed citations

20.

Sampath, Deepak, Mario Castro, Dwight C. Look, & Michael J. Holtzman. (1999). Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. Journal of Clinical Investigation. 103(9). 1353–1361. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact